Humana Medicare Advantage Coverage Expands NanoKnife IRE Access for Prostate and Liver Cancer
ANGO sits 22% above its 52-week low of $9.39 on elevated volume (2.3× avg).
Summary
Humana, one of the largest Medicare Advantage insurers with about 7 million members, updated its coverage policy to apply LCD L40205 medical necessity criteria for NanoKnife IRE, effective October 1, 2026. This expands reimbursement access for AngioDynamics' NanoKnife System in favorable intermediate-risk prostate cancer and certain liver tumors. The policy follows Category I CPT codes effective January 1, 2026, and Palmetto GBA's final LCD effective July 5, 2026, marking another reimbursement milestone. Broader coverage from a major payer could accelerate NanoKnife adoption and revenue growth, though prior authorization and plan terms still apply. AngioDynamics recently reported Q1 FY2027 revenue of $80.9M and appointed a new CEO effective November 2, 2026.
At the time of this announcement, ANGO was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $458.4M. The 52-week trading range was $9.39 to $16.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.